Timothy A. Springer - 18 Mar 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Director, 10%+ Owner
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer
Issuer symbol
RNAC
Transactions as of
18 Mar 2025
Net transactions value
+$1,371,154
Form type
4
Filing time
20 Mar 2025, 19:50:25 UTC
Previous filing
07 Feb 2025
Next filing
09 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Purchase $212,599 +14,740 +0.17% $14.42 8,546,202 18 Mar 2025 Direct F1
transaction RNAC Common Stock Purchase $302,962 +20,234 +0.24% $14.97 8,566,436 19 Mar 2025 Direct F2
transaction RNAC Common Stock Purchase $855,593 +54,889 +0.64% $15.59 8,621,325 20 Mar 2025 Direct F3
holding RNAC Common Stock 330,695 18 Mar 2025 By wife
holding RNAC Common Stock 529,798 18 Mar 2025 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $13.7242 to $14.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $14.85 to $15.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $15.00 to $15.9222. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.